In Vivo - Strategic Analysis For Medtech And Pharma Leaders since 1981
Podcasts
• By
Juho Jalkanen, CEO of Faron Pharma, discusses the importance of addressing unmet medical needs in cancer through breaking treatment resistance and developing long-term solutions, as well as the potential of its Phase II asset bexmarilimab.
Growth
Innovation
• By
This is Part 1 of a 2-part profile of Hans Clevers, Head of Pharma Research and Early Development at Roche.
• By
Artiva Biotherapeutics is hoping its NK cell therapy approach, which uses un-engineered cells, will prove effective in both oncologic and autoimmune indications and safe enough to be given in the community setting.
Leadership
Market Access
• By
Takeda’s head of gastroenterology talked to In Vivo about the major’s plans for finding biomarkers for Crohn’s disease as part of a Euro-wide prevention and interception trial.